Fig. 4.

Percentage of T cell subpopulations a effector memory CD4⁺, b effector memory CD8⁺, c effector CD4⁺, d effector CD8⁺, e naïve CD4⁺, f naïve CD8⁺, g central memory CD4⁺, h central memory CD8⁺ at baseline, during and after therapy. Lenalidomide was administered on weeks 1–16 and alemtuzumab weeks 5–16. * p < 0.05, ** p < 0.01, *** p < 0.001